Sumitomo Pharma Oncology Presented Preliminary Data From Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients With Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition
Sumitomo Pharma Oncology presented new data from the ongoing Phase 1/2 study evaluating TP-3654.
Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition
Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654
Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-0390, an Investigational Emopamil-binding Protein (EBP) Inhibitor for the Treatment of Brain Cancer
Sumitomo Pharma Oncology recently announced the U.S. FDA granted Orphan Drug Designation for DSP-0390, an investigational emopamil-binding protein (EBP) inhibitor for the treatment of brain cancer.
